📣 VC round data is live. Check it out!

Jointown Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Jointown Pharmaceutical and similar public comparables like Clicks Group, Nahdi Medical, Sugi Holdings, Yifeng Pharmacy and more.

Jointown Pharmaceutical Overview

About Jointown Pharmaceutical

Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and mainly serves medical institutions, wholesale enterprises, and retail pharmacies.


Founded

1999

HQ

China

Employees

30.2K

Sectors

Financials (LTM)

Revenue: $24B
EBITDA: $692M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Jointown Pharmaceutical Financials

Jointown Pharmaceutical reported last 12-month revenue of $24B and EBITDA of $692M.

In the same LTM period, Jointown Pharmaceutical generated $2B in gross profit, $692M in EBITDA, and $335M in net income.

Revenue (LTM)


Jointown Pharmaceutical P&L

In the most recent fiscal year, Jointown Pharmaceutical reported revenue of $24B and EBITDA of $753M.

Jointown Pharmaceutical is profitable as of last fiscal year, with gross margin of 8%, EBITDA margin of 3%, and net margin of 1%.

See analyst estimates for Jointown Pharmaceutical
LTMLast FY202320242025202620272028
Revenue$24B$24B$22B$22B$24B
Gross Profit$2B$2B$2B$2B$2B
Gross Margin8%8%8%8%8%
EBITDA$692M$753M$745M$846M$753M
EBITDA Margin3%3%3%4%3%
EBIT Margin2%3%3%3%3%
Net Profit$335M$330M$318M$367M$330M
Net Margin1%1%1%2%1%

Financial data powered by Morningstar, Inc.

Jointown Pharmaceutical Stock Performance

Jointown Pharmaceutical has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


Jointown Pharmaceutical's stock price is $0.76.

Jointown Pharmaceutical share price increased by 0.1% in the last 30 days, and by 0.3% in the last year.

Jointown Pharmaceutical has an EPS (earnings per share) of $0.07.

See more trading valuation data for Jointown Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B0.0%0.1%-2.4%0.3%$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Jointown Pharmaceutical Valuation Multiples

Jointown Pharmaceutical trades at 0.2x EV/Revenue multiple, and 5.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Jointown Pharmaceutical

EV / Revenue (LTM)


Jointown Pharmaceutical Financial Valuation Multiples

As of May 4, 2026, Jointown Pharmaceutical has market cap of $4B and EV of $4B.

Jointown Pharmaceutical has a P/E ratio of 11.4x.

LTMLast FY202320242025202620272028
EV/Revenue0.2x0.2x0.2x0.2x0.2x
EV/EBITDA5.7x5.3x5.3x4.7x5.3x
EV/EBIT7.5x6.7x6.0x6.4x6.7x
EV/Gross Profit2.2x2.2x2.2x2.3x2.2x
P/E11.4x11.6x12.0x10.4x11.6x
EV/FCF13.3x7.3x12.9x13.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Jointown Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Jointown Pharmaceutical Margins & Growth Rates

Jointown Pharmaceutical grew revenue by 6% but EBITDA decreased by 6% in the last fiscal year.

In the most recent fiscal year, Jointown Pharmaceutical reported gross margin of 8%, EBITDA margin of 3%, and net margin of 1%.

See estimated margins and future growth rates for Jointown Pharmaceutical

Jointown Pharmaceutical Margins

Last FY202420252026202720282029
Gross Margin8%8%8%7%
EBITDA Margin3%4%3%3%
EBIT Margin3%3%3%2%
Net Margin1%2%1%1%
FCF Margin1%1%1%

Jointown Pharmaceutical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%1%6%6%
Gross Profit Growth0%(2%)6%0%
EBITDA Growth(6%)14%(11%)(6%)
EBIT Growth(4%)(7%)(4%)(4%)
Net Profit Growth5%15%(10%)5%
FCF Growth(43%)(3%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Jointown Pharmaceutical Operational KPIs

Jointown Pharmaceutical's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.0M for the same period.

Jointown Pharmaceutical's Rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jointown Pharmaceutical's Rule of X is 17% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Jointown Pharmaceutical
LTMLast FY202320242025202620272028
Rule of 409%9%
Bessemer Rule of X18%17%
Revenue per Employee$0.8M
Opex per Employee$0.0M
S&M Expenses to Revenue3%3%1%1%1%
G&A Expenses to Revenue2%2%1%1%1%
R&D Expenses to Revenue0%0%0%0%0%
Opex to Revenue5%5%5%5%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Jointown Pharmaceutical Competitors

Jointown Pharmaceutical competitors include Clicks Group, Nahdi Medical, Sugi Holdings, Yifeng Pharmacy, CR Pharmaceutical, DaShenLin Pharmaceutical, COSMOS Pharmaceutical, Sundrug, Fragua and Ebos Group.

Most Jointown Pharmaceutical public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Clicks Group1.3x1.2x9.3x9.0x
Nahdi Medical1.4x1.4x8.5x8.4x
Sugi Holdings0.6x0.5x9.7x7.9x
Yifeng Pharmacy0.9x0.9x5.3x7.3x
CR Pharmaceutical0.3x0.3x4.1x4.3x
DaShenLin Pharmaceutical0.7x0.7x5.4x5.5x
COSMOS Pharmaceutical0.5x0.5x7.7x7.7x
Sundrug0.5x0.5x6.3x6.3x

This data is available for Pro users. Sign up to see all Jointown Pharmaceutical competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Jointown Pharmaceutical

When was Jointown Pharmaceutical founded?Jointown Pharmaceutical was founded in 1999.
Where is Jointown Pharmaceutical headquartered?Jointown Pharmaceutical is headquartered in China.
How many employees does Jointown Pharmaceutical have?As of today, Jointown Pharmaceutical has over 30K employees.
Is Jointown Pharmaceutical publicly listed?Yes, Jointown Pharmaceutical is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Jointown Pharmaceutical?Jointown Pharmaceutical trades under 600998 ticker.
When did Jointown Pharmaceutical go public?Jointown Pharmaceutical went public in 2010.
Who are competitors of Jointown Pharmaceutical?Jointown Pharmaceutical main competitors include Clicks Group, Nahdi Medical, Sugi Holdings, Yifeng Pharmacy, CR Pharmaceutical, DaShenLin Pharmaceutical, COSMOS Pharmaceutical, Sundrug, Fragua, Ebos Group.
What is the current market cap of Jointown Pharmaceutical?Jointown Pharmaceutical's current market cap is $4B.
What is the current revenue of Jointown Pharmaceutical?Jointown Pharmaceutical's last 12 months revenue is $24B.
What is the current revenue growth of Jointown Pharmaceutical?Jointown Pharmaceutical revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Jointown Pharmaceutical?Current revenue multiple of Jointown Pharmaceutical is 0.2x.
Is Jointown Pharmaceutical profitable?Yes, Jointown Pharmaceutical is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Jointown Pharmaceutical?Jointown Pharmaceutical's last 12 months EBITDA is $692M.
What is Jointown Pharmaceutical's EBITDA margin?Jointown Pharmaceutical's last 12 months EBITDA margin is 3%.
What is the current EV/EBITDA multiple of Jointown Pharmaceutical?Current EBITDA multiple of Jointown Pharmaceutical is 5.7x.
How many companies Jointown Pharmaceutical has acquired to date?Jointown Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Jointown Pharmaceutical has invested to date?Jointown Pharmaceutical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Jointown Pharmaceutical

Lists including Jointown Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial